Skip to main content

Lineage Cell Therapeutics, Inc.

LCTX
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000876343

In the last 90 days, Lineage Cell Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $153.0M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 17, 2026
$206.4M
Insider buysLast 90 days, $17.1K in total
1
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +2 vs. previous quarter
132
13F valueReported value at the end of Q2 2026
$153.0M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$14.6M
+53.2% year over year
Net income, FY2025
-$63.5M
No comparable prior period
Free cash flow, FY2025
-$19.4M
No comparable prior period
Revenue, Q3 FY2026
$1.43M
−61.0% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $63.5M (436.5% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
24.3M
Shares sold short
Change
−1.58M
−6.1% vs. previous
Days to cover
19.27
At average daily volume

Superinvestors holding LCTX, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding LCTX at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Lineage Cell Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 16, 2026 (view filing)5:00 PM ETNov 16Same dayHowe Jill AnnChief Financial OfficerPPurchase+20.0K$0.855+$17.1K+78.4%45.5K after
Mar 12, 2026 (view filing)Mar 12Same dayCulley Brian MPresident and CEOPPurchase+15.0K$1.63+$24.4K+6.2%255.5K after
Jan 28, 2025 (view filing)7:49 PM ETJan 271 dayBroadwood Partners, L.P. and 2 othersDirector, 10% OwnerPPurchase+7.89M$0.76+$6.00M+18.9%49.6M after
Jan 28, 2025 (view filing)7:49 PM ETJan 271 dayBroadwood Partners, L.P. and 2 othersDirector, 10% OwnerPPurchase0–$00.0%49.6M after
Jan 28, 2025 (view filing)7:49 PM ETJan 271 dayBroadwood Partners, L.P. and 2 othersDirector, 10% OwnerPPurchase+7.89M$0.00$0–7.89M afterDerivative
Jan 28, 2025 (view filing)7:49 PM ETJan 271 dayBroadwood Partners, L.P. and 2 othersDirector, 10% OwnerPPurchase+7.89M$0.00$0–7.89M afterDerivative
Nov 26, 2024 (view filing)Nov 26Same dayHowe Jill AnnChief Financial OfficerPPurchase+15.0K$0.59+$8.85K+142.9%25.5K after
Nov 26, 2024 (view filing)Nov 26Same daySamuel George A. IIIGeneral CounselPPurchase+15.0K$0.60+$9.00K+208.8%22.2K after
Nov 25, 2024 (view filing)Nov 223 daysMulroy Michael H.DirectorPPurchase+40.0K$0.57+$22.8K+15.5%298.6K after
Nov 22, 2024 (view filing)Nov 211 dayCulley Brian MPresident and CEOPPurchase+40.0K$0.60+$24.0K+25.8%194.8K after

Top 10 13F holders, Q2 2026

See all 132 holders

The largest institutional positions in Lineage Cell Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding LCTX in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Broadwood Capital Inc49,560,992$64.9M3.39%00.0%Unchanged
BlackRock, Inc.13,186,895$17.3M0.00%+9,322,138+241.2%Added
Vanguard Capital Management LLC9,054,918$11.9M0.00%+736,233+8.9%Added
Defender Capital, LLC.6,598,899$8.64M2.81%−130,700−1.9%Reduced
Geode Capital Management, LLC5,299,457$6.94M0.00%+2,776,343+110.0%Added
Raffles Associates LP5,197,788$6.81M5.80%−165,000−3.1%Reduced
Fifth Third Bancorp4,600,000$6.03M0.01%00.0%Unchanged
Millennium Management LLC3,018,567$3.95M0.00%−2,542,807−45.7%Reduced
State Street Corp2,314,180$3.03M0.00%+1,224,069+112.3%Added
Vanguard Fiduciary Trust Co1,668,629$2.19M0.00%+344,471+26.0%Added

Holders of 5% or more of LCTX

See all 3 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Lineage Cell Therapeutics, Inc..

Largest holders of LCTX from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Broadwood Partners, L.P.13D/A23.10%57.8M shares−1.40 ppfrom 24.50%Mar 16, 20216 filingsNov 14, 2025SEC
BlackRock, Inc.13G5.30%13.2M shares+4.30 ppfrom 1.00%Oct 22, 20246 filingsJul 29, 2026SEC
Chernett Jorey13G5.00%11.4M sharesNewSep 26, 20251 filingSep 26, 2025SEC